[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitive Intelligence: Hologic in the Global Diagnostic Imaging Sector

February 2013 | 49 pages | ID: C50A9251586EN
Venture Planning Group

US$ 1,960.00 US$ 2,450.00 -20 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This strategic assessment of Hologic, one of the world's leading diagnostic imaging companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The new report from Venture Planning Group presents a comprehensive analysis of the company's performance, capabilities, goals, and strategies in the global diagnostic imaging market.

Contains 49 pages and 6 tables
SECTION I: EXECUTIVE SUMMARY

A 3-15 page synopsis of key sections.

SECTION II: BUSINESS ORGANIZATION

History of the company’s diagnostic imaging business evolution, which is important to understanding
the corporate culture, management mentality and strategies.
Recent acquisitions, divestitures and major organizational changes.
Current organizational structure.

SECTION III: SENIOR MANAGEMENT

Names, titles and background of key executives.

SECTION IV: FACILITIES AND EMPLOYEES

Administrative, manufacturing and R&D facilities in the U.S. and abroad.
Manufacturing practices.
New plants under construction.
The U.S. and international work force size and distribution.

SECTION V: TECHNOLOGICAL KNOW-HOW

Internally developed and acquired diagnostic imaging and related technologies, including X-ray,
ultrasound, MRI, CT, nuclear medicine, PET, PACS, and others.

SECTION VI: PRODUCT PORTFOLIO

Placements and installed base of major systems in the U.S. and abroad, by modality.
Review of major product lines.
Applications, advantages and weaknesses of leading products.

SECTION VII: MARKETING TACTICS

Promotional tactics.
Distribution approaches.
Product service and support.
Customer relations.

SECTION VIII: FINANCIAL ANALYSIS

Estimated sales and operating profit by division, geographic region and product line.
Five-year sales and operating profit performance.

SECTION IX: R&D EXPENDITURES AND MAJOR PROGRAMS

Estimated R&D budget.
Research facilities and staff.
New technologies, systems and applications in development.

SECTION X: COLLABORATIVE ARRANGEMENTS

Joint ventures, distribution, O.E.M. and licensing partners, both industrial and academic.
Terms of collaborative agreements and specific products involved.

SECTION XI: STRATEGIC DIRECTION

Specific business, new product development and marketing strategies.
Anticipated acquisitions, joint ventures and divestitures.


More Publications